Blockchain Registration Transaction Record
Tonix's TNX-1500 Phase 1 Data Published: Promising Step for Kidney Transplant
Tonix Pharmaceuticals announces publication of Phase 1 data for TNX-1500 in Journal of Clinical Immunology, showing safety and tolerability, supporting advancement to Phase 2 kidney transplant rejection study.
This news matters because it showcases the progress of TNX-1500, a potential new treatment to prevent kidney transplant rejection, a critical unmet need. With Phase 1 data demonstrating safety and tolerability, and a clear path to Phase 2 trials, this could offer hope for thousands of patients awaiting or living with kidney transplants. For investors, positive clinical data strengthens Tonix's immunology pipeline and may enhance the company's valuation.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x44db3808b616057b00f93f86216fef3509a85696f918586dba475a088724102c |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | frogou8X-6d8b72656402acfedf34833732ece6c5 |